Vimarsana
Biggest News Aggregation in the World

Page 17 - Opgen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Opgen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Opgen Today - Breaking & Trending Today

OpGen Announces Pricing of $7.5 Million Public Offering - Vimarsana News

OpGen Announces Pricing of $7.5 Million Public Offering

ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power...

OpGen, Inc.: OpGen Announces Pricing of $7.5 Million Public Offering - Vimarsana News

OpGen, Inc.: OpGen Announces Pricing of $7.5 Million Public Offering

ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, "OpGen" or "the Company"), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to

OpGen Reports Third Quarter 2022 Financial Results and - Vimarsana News

OpGen Reports Third Quarter 2022 Financial Results and

Completes first two commercial customer installations for Acuitas AMR Gene PanelOpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG...

OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com - Vimarsana News

OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN – Get Rating) in a report released on Wednesday. The brokerage set a “sell” rating on the medical research company’s stock. A number of other research firms have also issued reports on OPGN. Alliance Global Partners lowered OpGen to a “neutral” rating in a […]

OpGen Reports Second Quarter 2022 Financial Results and - Vimarsana News

OpGen Reports Second Quarter 2022 Financial Results and

Total Q2 2022 revenues of $1.0 million with product sales a key growth driverFirst two commercial customer contracts for Acuitas AMR Gene Panel signed in...